NICE rejects MSD/Pfizer's combination in untreated kidney ca...

NICE said “no” to NHS funding for a combination of MSD’s Keytruda (pembrolizumab) immunotherapy and Pfizer’s Inlyta (axitinib) in untreated kidney cancer, citing uncertainties about its lon

Immunicum shares fall despite “fantastic” kidney cancer data

Merck and Pfizer's Bavencio approved for renal cell carcinom...

Merck KGaA and Pfizer’s immunotherapy Bavencio (avelumab) has been approved by the FDA in combination with Pfizer’s Inlyta (axitinib) for the first-line treatment of

Keytruda combo set to become "standard of care" in kidney ca...

Analysts are predicting that a combination of Merck’s Keytruda and Pfizer’s Inlyta will become the standard of care in renal cell carcinoma (RCC) thanks to impressive trial results and a pr

Clinigen buys remaining rights to Novartis cancer drug

UK pharma Clinigen is to buy the remaining rights to Novartis’ cancer drug Proleukin, in a deal worth up to $210 million.

EU approves Ipsen's Cabometyx in first line kidney cancer

Drug looks set to become core part of Ipsen's cancer offering